GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
Subjects(RVK)
  • 1
    In: Blood, American Society of Hematology, Vol. 105, No. 5 ( 2005-03-01), p. 2206-2213
    Abstract: 4-1BB, a member of the tumor necrosis factor (TNF) receptor superfamily, is a costimulator for activated T cells. Previous studies have established that treatment with agonistic anti–4-BB monoclonal antibody (3H3) is effective in reversing the progression of spontaneous systemic lupus erythematosus. Its therapeutic effect is mediated by suppression of autoantibody production. In this report, we show that a single injection of 3H3 blocks chronic graft-versus-host disease (cGVHD) in the parent-into-F1 model. In particular, donor CD4+ T cells are rapidly eliminated from host spleens by activation-induced cell death after 4-1BB triggering. Since donor CD4+ T cells are required for the development of cGVHD, and 3H3-mediated inhibition of autoantibody production occurs without donor CD8+ T cells, 3H3 blocks cGVHD by preventing alloreactive donor CD4+ T cells from activating host B cells. Importantly, 3H3 treatment can reverse the progression of advanced cGVHD. Our findings indicate that agonistic anti–4-1BB monoclonal antibody has potential as an immunotherapeutic agent for preventing and treating cGVHD.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 16_suppl ( 2023-06-01), p. e14516-e14516
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e14516-e14516
    Abstract: e14516 Background: V-set and immunoglobulin domain-containing 4 (VSIG4) is one of the B7 family-related proteins that includes PD-L1, VISTA, and CTLA4 ligand. VSIG4 overexpression is correlated with poor prognosis in patients with ovarian cancer, lung cancer, gastric cancer, high-grade glioma, and multiple myeloma. VSIG4 is also known to function as a receptor for complements and the negative regulation of T cell proliferation. Although VSIG4 is highly expressed in tissue-resident macrophages and tumor-associated macrophages (TAM), its role in the tumor microenvironment (TME) is not fully elucidated. Methods: We previously developed a therapeutic antibody, EU103, in a humanized form of a VSIG4-specific antibody. Most importantly, we demonstrated that EU103 directly acts on the tumor-associated macrophages (TAM) and mechanistically induces repolarization of TAM to tumor killing M1 macrophages and blocks VSIG4-mediated T cell suppression, eventually leading to CD8 + T cell proliferation and tumor suppression in a PBMC-humanized human lung cancer mouse model. Results: Expanding our previous findings with the therapeutic potential of EU103 in a non-small cell lung carcinoma (NSCLC), here, we also proved its therapeutic effect in human ovarian cancer. Firstly, TAMs isolated from ovarian cancer patients express high levels of VSIG4 with immunosuppressive M2 macrophage phenotype. Secondly, EU103 treatment of the TAMs in in vitro studies induces M2-to-M1 conversion and activation of T cells in the ascites leading to ovarian tumor cell killing in a dose-dependent manner. Thirdly, in vivo therapeutic efficacy of EU103 in ovarian cancer, especially through M2-to-M1 conversion, is also verified in both CD34 + cell and peripheral blood mononuclear cell (PBMC) humanized mouse models. Finally, we validate the results above by treating ovarian cancer patient-derived ascites with EU103. Conclusions: Almost 300,000 women are diagnosed with ovarian cancer worldwide each year, and ovarian cancer ranks fifth in cancer deaths among women. In the United States alone, we expect approximately 20,000 new diagnoses and more than 12,000 deaths for this year. Given our findings in this study and clinical significance, we propose here the therapeutic potential of EU103, previously developed by our proprietary antibody discovery and engineering technology, in ovarian cancer.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 191, No. 5 ( 2013-09-01), p. 2657-2664
    Abstract: Damage-associated molecular patterns released from damaged kidney cells initiate postischemic inflammation, an essential step in the progression of kidney ischemia–reperfusion injury (IRI). However, the mechanism that coordinates this highly specific process in ischemic kidneys remains to be clarified. Previously, we demonstrated that CD137 from NK cells specifically stimulates CD137 ligand (CD137L) on tubular epithelial cells (TECs) such that TECs produced the high CXCR2 chemokine levels required for neutrophil chemotaxis. We report in the present study that endogenous TLR2 ligands released from ischemic TECs induce CCR5 chemokine expression, which is critical to promoting NK cell recruitment. By implanting CD137L−/− TECs into the kidney capsule of TLR2−/− mice, we further showed that TLR2-mediated NK cell recruitment is an uncoupled event that can occur independently of CD137L signaling in TECs, which is responsible for recruiting neutrophils. Therefore, our findings identify TECs as both a target for kidney damage and also as a master regulator that actively modulates stepwise signaling, leading to the initiation and amplification of acute sterile inflammation that inflicts kidney IRI. Being clinically important, the signaling pathway of innate receptors in epithelial cells may therefore be a good target to block acute sterile inflammation resulting from tissue damage, including kidney IRI.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2013
    detail.hit.zdb_id: 1475085-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 109, No. 1 ( 2012-01-03)
    Abstract: The results of our investigation identify a pathway for acute tissue inflammation that involves the NK cell–epithelial–neutrophil axis in which CD137–CD137L interactions play a critical role in the signaling process that induces inflammation ( Fig. P1 ). We have demonstrated one especially important finding: Reverse signaling through a member of the costimulatory ligand family (CD137L) propagates tissue inflammation in a disease context. This process may be implicated in various other types of acute tissue inflammation. Finally, we asked which CD137-expressing immune cells could induce TECs to trigger the CD137L signaling pathway leading to production of CXCL1 and CXCL2. The membrane that separates the TEC layer from other connective tissue cells was disrupted rapidly after renal IRI was induced, and natural killer (NK) cells approached TECs. Expression of CD137 was induced on infiltrating NK cells soon after the induction of renal IRI. Transferring normal, unmutated NK cells completely restored renal IRI in CD137-KO mice. In addition, activated NK cells that expressed CD137 on their cell surface stimulated TECs to produce high levels of functional CXCL1 and CXCL2. We further asked how CD137L signals mediate renal IRI. Other studies have demonstrated that deficiency of signaling-receptor molecules of the TLR family (namely, TLR2 and TLR4) in TECs results in severe defects in neutrophil infiltration in renal IRI ( 3 , 4 ), as seen in CD137-KO mice. To investigate whether CD137L signals in TECs are a prerequisite for renal IRI, we devised an experimental system in which signaling through CD137L in TECs is allowed in CD137L-KO mice. Implantation of normal, unmutated TECs in CD137L-KO mice restored renal IRI. Reduced production of signaling molecules of the chemokine family, namely CXC receptor ligand 1 (CXCL1) and CXC receptor ligand 2 (CXCL2), in TECs and the consequent impairment in recruitment of neutrophils were associated with the resistance to renal IRI in CD137 or CD137L-KO mice. In vitro stimulation of TECs by using fusion proteins rapidly induced the release of CXCL1 and CXCL2, in turn inducing migration of neutrophils in a CXC receptor 2 (CXCR2)-dependent manner. We began our studies by observing that the signaling receptor molecule CD137 ligand (CD137L) was constitutively (constantly) expressed on the surface of TECs and that mice with mutations preventing the expression of its receptor (CD137-KO mice) were severely impaired in renal IRI. We asked how interactions between the CD137 receptor and the molecule that it recognizes (CD137L) mediate renal IRI. Initial experiments indicated that CD137 expression on hematopoietic cells (cells capable of developing into many types of blood cells) were required for renal IRI. Stimulation using specific molecules that target CD137 blocked rather than enhanced renal IRI, suggesting that reverse signaling through CD137L played a pivotal role in renal IRI. Further supporting this explanation, engagement of CD137L (using a recombinant or modified protein that fuses the ligand) resulted in complete recovery from renal IRI in CD137-KO mice. In the disorder known as “renal ischemia-reperfusion injury” (IRI), hypoxic (low oxygen supply) cell injuries occur early during the ischemic (low blood flow) phase, followed by inflammatory responses in the reperfusion phase (when blood flow returns). These injured cells release various inducers of inflammation, including proinflammatory cytokines (specific immune molecules) and endogenous danger signals recognized by a type of receptors called “Toll-like receptors” (TLRs). In kidneys with reduced blood flow (ischemic kidneys), activation of TLR and two types of specific immune molecules (cytokines and complements) induces expression of multiple proinflammatory molecules known as “chemokines.” The tubular epithelium is a major site for cell injury and for such changes. Epithelial cells known as “tubular epithelial cells” (TECs) usually are damaged. Even though the arrival of neutrophils to these damaged cells is characteristic of acute inflammation, it is not known precisely how damaged TECs regulate penetration of neutrophils (neutrophil infiltration) into postischemic kidneys. Inflammation, an important immune process, is triggered by a variety of stress conditions ( 1 ). Because epithelial cells line the surfaces of organs and internal cavities, they are particularly vulnerable to injuries by pathogenic microorganisms, toxic factors, and physical trauma. The resulting epithelial damage causes myriad changes, including many changes important in inflammation ( 2 ). Although progress has been made in understanding how molecules called “antigens” on the surfaces of stressed epithelial cells regulate immune cells, little is known about receptor molecules that permit immune cells to target such stressed epithelial cells. Here, we describe cellular signaling in a pathway involving a particular epithelial cell and the recruitment of immune players known as “neutrophils.”
    Type of Medium: Online Resource
    ISSN: 0027-8424 , 1091-6490
    RVK:
    RVK:
    Language: English
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date: 2012
    detail.hit.zdb_id: 209104-5
    detail.hit.zdb_id: 1461794-8
    SSG: 11
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Immunology & Cell Biology, Wiley, Vol. 83, No. 4 ( 2005-08), p. 344-351
    Abstract: 4‐1BB costimulates T cells to carry out effector functions such as eradication of established tumours. 4‐1BB (CD137) is a member of the TNF receptor family, and its triggering by either 4‐1BB ligand or antibody ligation induces T‐cell activation and growth. We analysed tumour‐infiltrating lymphocytes (TIL) in the experimental B16F10 melanoma model to determine the mechanisms involved in 4‐1BB‐mediated tumour suppression. 4‐1BB +/+ mice survived longer than 4‐1BB –/– mice, and survival was further prolonged by triggering 4‐1BB with an agonistic mAb. The number of metastatic B16F10 colonies in the lung was much greater in 4‐1BB –/– mice than in their 4‐1BB +/+ littermates. Administration of agonistic anti‐4‐1BB mAb increased the number of TIL in the tumour masses in the lungs of 4‐1BB +/+ mice. The numbers of CD4 + T, CD8 + T and CD11b + TIL increased in these mice. Anti‐4‐1BB mAb induced not only CD8 + 4‐1BB + T cells but also a CD8 + IFN‐γ + T‐cell population. B16F10 cells from the lungs of anti‐4‐1BB‐treated mice showed enhanced expression of MHC class Ι and II antigens compared with the same cells from control IgG‐treated mice. Thus, the increase in number of CD8 + T cells and enhanced MHC Ι and II expression in B16F10 cells that result from augmented IFN‐γ production in response to anti‐4‐1BB mAb may lead to suppression of tumour growth and metastasis.
    Type of Medium: Online Resource
    ISSN: 0818-9641 , 1440-1711
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2005
    detail.hit.zdb_id: 2011707-3
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Current Eye Research, Informa UK Limited, Vol. 26, No. 3-4 ( 2003-01), p. 225-229
    Type of Medium: Online Resource
    ISSN: 0271-3683 , 1460-2202
    RVK:
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2003
    detail.hit.zdb_id: 1483048-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Stem Cells and Development, Mary Ann Liebert Inc, Vol. 23, No. 23 ( 2014-12), p. 2831-2840
    Type of Medium: Online Resource
    ISSN: 1547-3287 , 1557-8534
    Language: English
    Publisher: Mary Ann Liebert Inc
    Publication Date: 2014
    detail.hit.zdb_id: 2142305-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Immunology, Wiley, Vol. 121, No. 3 ( 2007-07), p. 349-358
    Type of Medium: Online Resource
    ISSN: 0019-2805 , 1365-2567
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2007
    detail.hit.zdb_id: 2006481-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Elsevier BV ; 1999
    In:  Current Opinion in Immunology Vol. 11, No. 3 ( 1999-6), p. 340-345
    In: Current Opinion in Immunology, Elsevier BV, Vol. 11, No. 3 ( 1999-6), p. 340-345
    Type of Medium: Online Resource
    ISSN: 0952-7915
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 1999
    detail.hit.zdb_id: 2019218-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    The American Association of Immunologists ; 2009
    In:  The Journal of Immunology Vol. 182, No. 7 ( 2009-04-01), p. 4107-4115
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 182, No. 7 ( 2009-04-01), p. 4107-4115
    Abstract: 4-1BB (CD137) is expressed on dendritic cells (DCs) and its biological function has remained largely unresolved. By comparing 4-1BB-intact (4-1BB+/+) and 4-1BB-deficient (4-1BB−/−) DCs, we found that 4-1BB was strongly induced on DCs during the maturation and that DC maturation was normal in the absence of 4-1BB. However, DC survival rate was low in the absence of 4-1BB, which was due to the decreased Bcl-2 and Bcl-xL in 4-1BB−/− DCs compared with 4-1BB+/+ DCs after DC maturation. Consistent with these results, 4-1BB−/− DCs showed an increased turnover rate in steady state and more severely decreased in spleen by injecting LPS compared with 4-1BB+/+ DCs. When OVA-pulsed DCs were adoptively transferred to recipient mice along with OVA-specific CD4+ T cells, 4-1BB−/− DCs did not properly migrate to the T cell zone in lymph nodes and poorly induced proliferation of CD4+ T cells, although both DCs comparably expressed functional CCR7. Eventually, 4-1BB−/− DCs generated a reduced number of OVA-specific memory CD4+ T cells compared with 4-1BB+/+ DCs. To further assess the role of 4-1BB on DC longevity in vivo, 4-1BB+/+ and 4-1BB−/− C57BL/6 were administrated with Propionibacterium acnes that develop liver granuloma by recruiting DCs. Number and size of granuloma were reduced in the absence of 4-1BB, but the inflammatory cytokine level was comparable between the mice, which implied that the granuloma might be reduced due to the decreased longevity of DCs. These results demonstrate that 4-1BB on DCs controls the duration, DC-T interaction, and, therefore, immunogenicity.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2009
    detail.hit.zdb_id: 1475085-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...